RTX-134 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 240 | Phenylketonuria | 1 |
240. Phenylketonuria
Clinical trials : 143 / Drugs : 90 - (DrugBank : 10) / Drug target gene : 1 - Drug target pathways : 5
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04110496 (ClinicalTrials.gov) | January 29, 2020 | 23/9/2019 | Safety and Tolerability of RTX-134 in Adults With Phenylketonuria | A Phase 1b Open-Label Single Dose Safety, Tolerability, and Pharmacokinetics Study of RTX-134 in Adults With Phenylketonuria | Phenylketonurias | Drug: RTX-134 | Rubius Therapeutics | NULL | Terminated | 18 Years | N/A | All | 1 | Phase 1 | United States |